High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL

Cancer Research

Volumn 66, Issue 20, 2006, Pages 9818-9828

  Goldstein, Alisa M ^a   Chan, May ^c   Harland, Mark ^c   Gillanders, Elizabeth M ^b   Hayward, Nicholas K ^e   Avril, Marie Francoise ^g   Azizi, Esther ⁱ   Bianchi Scarra, Giovanna ^j   Bishop, D Timothy ^c   Bressac De Paillerets, Brigitte ^g   Bruno, William ^j   Calista, Donato ^k   Albright, Lisa A Cannon ^l   Demenais, Florence ^h   Elder, David E ⁿ   Ghiorzo, Paola ^j   Gruis, Nelleke A ^o   Hansson, Johan ^p   Hogg, David ^r   Holland, Elizabeth A ^f   Kanetsky, Peter A ⁿ   Kefford, Richard F ^f   Landi, Maria Teresa ^a   Lang, Julie ^d   Leachman, Sancy A ^m   MacKie, Rona M ^d   Magnusson, Veronica ^p   Mann, Graham J ^f   Niendorf, Kristin ^s   Bishop, Julia Newton ^c   Palmer, Jane M ^e   Puig, Susana ^t   Puig Butille, Joan A ^t   De Snoo, Femke A ^o   Stark, Mitchell ^e   Tsao, Hensin ^s   Tucker, Margaret A ^a   Whitaker, Linda ^c   Yakobson, Emanuel ⁱ   Malvehy, J ^t   Badenas, C ^t   Cervera, R ^t   Cuellar, Francisco ^t,u   Martí, Rosa ^v   Brunet Vidal, Joan ^w,x   Yang, Guang ^s   Martin, Nicholas ^e   Whiteman, David ^e   Green, Adele ^e   Aitken, Joanne ^y   Minghetti, Paola ^k   Mantelli, Michela ^j   Pastorino, Lorenza ^j   Nasti, Sabina ^j   Gargiulo, Sara ^j   Gliori, Sara ^z   Mistry, Sushila ^c   Randerson Moor, Juliette ^c   Bergman, Wilma ^o   Ter Huurne, Jeanet A C ^o   Van Der Drift, Clasine ^o   Van Mourik, Leny ^o   Out Luiting, Coby ^o   Van Nieuwpoort, Frans ^o   Chaudru, Valerie ^h   Chompret, Agnes ^g   Kanengiesser, Caroline ^g   Michel, J L ^ab   Grange, F ^ab   Sassolas, B ^ab   Limacher, J M ^ab   Couillet, D ^ab   Truchetet, F ^ab   Cesarini, J P ^ab   Boitier, F ^ab   Chevrant Breton, J ^ab   Lasset, C ^ab   Longy, M ^ab   Joly, P ^ab   Basset Seguin, N ^ab   Lesimple, T ^ab   Dugast, C ^ab   Ganguly, Arupa ⁿ   Ming, Michael ⁿ   Van Belle, Patricia ⁿ   Platz, Anton ^p   Egyhazi, Suzanne ^p   Tuominen, Rainer ^p   Linden, Diana ^p   Schmid, Helen ^aa   Scope, Alon ⁱ   Pavlotsky, Felix ⁱ   Friedman, Eitan ⁱ   Eliason, Mark ^m   Ingvar, Christian ^q   Borg, Ake ^q   Westerdahl, Johan ^q   Masback, Anna ^q   Olsson, Hakan ^q   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

ⁱ TEL AVIV UNIVERSITY   (Israel)

^j UNIVERSITY OF GENOA   (Italy)

^k BUFALINI HOSPITAL   (Italy)

^l UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF UTAH   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^q LUND UNIVERSITY HOSPITAL   (Sweden)

^r UNIVERSITY OF TORONTO   (Canada)

^s MASSACHUSETTS GENERAL HOSPITAL   (United States)

^t UNIVERSITY OF BARCELONA   (Spain)

^u Unidad Durango   (Mexico)

^v UNIVERSITY OF LLEIDA   (Spain)

^w HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^x CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^y CANCER COUNCIL QUEENSLAND   (Australia)

^z UNIVERSITY OF GENOA   (Italy)

^aa WESTMEAD HOSPITAL   (Australia)

^ab Leiden University Medical Center ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; PROTEIN P14ARF; PROTEIN P16;

AMINO ACID SEQUENCE; ARTICLE; AUSTRALIA; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; DEMOGRAPHY; FRANCE; GENE DELETION; GENE MUTATION; HUMAN; ITALY; MELANOMA; MISSENSE MUTATION; MUTATION; NETHERLANDS; PANCREAS CANCER; PRIORITY JOURNAL; SPAIN; SWEDEN; UNITED KINGDOM; UVEA MELANOMA;

ADULT; AGE FACTORS; AMINO ACID SEQUENCE; ANIMALS; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEOPLASMS, NERVE TISSUE; PANCREATIC NEOPLASMS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SKIN NEOPLASMS; UVEAL NEOPLASMS;

EID: 33750567811     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0494     Document Type: Article

References (60)

1. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
2. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:22-6.
3. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-7.
4. Serrano M, Gomez-Lahoz E, DePinho RA, Beach D, Barsagi D. Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science 1995;267:249-52.
5. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
6. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
7. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12:97-9.
8. Soufir N, Avril M-F, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 1998;7:209-16.
9. Molven A, Grimstvedt MB, Steine SJ, et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 2005;44:10-8.
10. Bergman W, Watson P, deJong J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome. Br J Cancer 1990;61:932-6.
11. INK4 mutations. N Engl J Med 1995;333:970-4.
12. Goldstein AM, Struewing JP, Fraser MC, Smith MW, Tucker MA. Prospective risk of cancer in CDKN2A germline mutation carriers. J Med Genet 2004;41:421-4.
13. Ghiorzo P, Ciotti P, Mantelli M, et al. Characterization of Ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999;83:441-8.
14. Borg A, Sandberg T, Nilsson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260-6.
15. Vasen HFA, Gruis NA, Frants RR, van der Velden PA, Hille ETM, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000;87:809-11.
16. Parker J, Florell SR, Alexander A, DiSario JA, Shami PJ, Leachman SA. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 2003; 139:1019-25.
17. Bahuau M, Vidaud D, Jenkins RB, et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998;58:2298-303.
18. ARF but not CDKN2A in a melanoma-neural system tumor syndrome family. Hum Mol Genet 2001;10:55-62.
19. ARF RNA processing in a melanoma/neurofibroma kindred. Genes Chromosomes Cancer 2001;31:398-401.
20. Rizos H, Puig S, Badenas C, et al. A melanoma-associated germline mutation in exon 1β inactivates p14ARF. Oncogene 2001;20:5543-7.
21. Hewitt C, Wu CL, Evans G, et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 2002;11:1273-9.
22. Kannengiesser C, Avril M-F, Spatz A, Laud K, Lenoir GM, Bressac de-Paillerets B. CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Genes Chromosomes Cancer 2003;38:265-8.
23. Flores JF, Pollock PM, Walker GJ, et al. Analysis of the CDKN2A, CDKN2B, and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 1997;15:2999-3005.
24. Whiteman DC, Milligan A, Welch J, Green AC, Hayward NK. Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst 1997;89:1460.
25. Aitken J, Welch J, Duffy D, et al. CDKN2A variants in a population-based sample of Queensland families with melanoma. J Natl Cancer Inst 1999;91:446-52.
26. INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 1999;25:339-48.
27. β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations. Oncogene 1997;15:515-23.
28. Harland M, Holland EA, Ghiorzo P, et al. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 2000;28:45-57.
29. Landi MT, Goldstein AM, Tsang S, et al. Genetic susceptibility in familial melanoma from North Eastern Italy. J Med Genet 2004;41:557-66.
30. Bergman W, Gruis NA, Frants RR. The Dutch FAMMM family material: clinical and genetic data. Cytogenet Cell Genet 1992;59:161-4.
31. Gruis NA, van der Velden PA, Sandkuijl LA, et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995;10:351-3.
32. Ruiz A, Puig S, Malvehy J, et al. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 1999;36:490-4.
33. Platz A, Hansson J, Mansson-Brahme E, et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997; 89:697-702.
34. Platz A, Hansson J, Ringborg U. Screening of germline mutations in the CDK4, CDKN2C, and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer 1998;78:13-5.
35. Hashemi J, Linder S, Platz A, Hansson J. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic nevus syndrome in Swedish melanoma kindreds. Melanoma Res 1999;9:21-30.
36. Borg A, Johannsson U, Johannson O, et al. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 1996;56:2497-500.
37. MacKie RM, Andrew N, Lanyon WG, Connor JM. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 1998;111:269-72.
38. Lang J, Boxer M, MacKie RM. CDKN2A mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families. Br J Dermatol 2005; 153:1121-5.
39. Newton Bishop JA, Harland M, Bennett DC, et al. Mutation testing in melanoma families: INK4A, CDK4, and INK4D. Br J Cancer 1999;80:295-300.
40. Yang G, Niendorf KB, Tsao H. A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred. J Invest Dermatol 2004;123:574-5.
41. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in American melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000;92:1006-10.
42. Eliason MJ, Larson AA, Flor-ell SR, et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 2006;126:660-6.
43. Grantham R. Amino acid difference formula to help explain protein evolution. Science 1974;85:862-4.
44. Henikoff S, Henikoff JG. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 1992;89:2264-8.
45. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
46. Higgins D, Thompson J, Gibson T, Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties, and weight matrix choice. Nucleic Acids Res 1994;22:4673-80.
47. Harland M, Taylor CF, Chambers PA, et al. A mutation hotspot at the p14ARF splice site. Oncogene 2005;24:4604-8.
48. Liu L, Dilworth D, Gao L, et al. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 1999;21:128-32.
49. Goldstein AM, Liu L, Shennan MG, Hogg D, Tucker MA, Struewing JP. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families. Br J Cancer 2001;85:527-30.
50. arf) and cdkn2b genes in 53 melanoma index cases considered to be at heightened risk of melanoma. J Med Genet 2006;43:39-47.
51. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002;94:894-903.
52. Miller MP, Kumar S. Understanding human disease mutations through the use of interspecific genetic variation. Hum Mol Genet 2001;10:2319-28.
53. Greenblatt MS, Beaudet JG, Gump JR, et al. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene 2003;22:1150-63.
54. Hashemi J, Bendahl P-O, Sandberg T, et al. Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families. Genes Chromosomes Cancer 2001;31:107-16.
55. Ciotti P, Struewing JP, Mantelli M, et al. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families. Am J Hum Genet 2000;67:311-9.
56. Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005;97:1507-15.
57. Mistry SH, Taylor C, Randerson-Moor JA, et al. Prevalence of 9p21 deletions in UK melanoma families. Genes Chromosomes Cancer 2005;44:292-300.
58. Marian C, Scope A, Laud K, et al. Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours. Br J Cancer 2005;92:2278-85.
59. Nielsen K, Ingvar C, Masback A, et al. Melanoma and nonmelanoma skin cancer in patients with multiple tumours-evidence for new syndromes in a population-based study. Br J Dermatol 2004;150:531-6.
60. Goldstein AM. Familial melanoma, pancreatic cancer, and germline CDKN2A mutations. Hum Mutat 2004;23:630.